Loading...

BioSig Technologies, Inc.

BSGMNASDAQ
Healthcare
Medical - Devices
$9.05
$1.91(26.75%)

BioSig Technologies, Inc. (BSGM) Stock Overview

Explore BioSig Technologies, Inc.’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

B

Score: 68.0/100

Key Financials

Market Cap227.1M
P/E Ratio-17.83
EPS (TTM)$-0.53
ROE-35.30%
Fundamental Analysis

AI Price Forecasts

1 Week$7.91
1 Month$5.54
3 Months$3.71
1 Year Target$0.47

BSGM Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of BioSig Technologies, Inc. (BSGM) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

Our forecasting models predict significant price movements, with a 12-month target of $0.47.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -17.83 and a market capitalization of 227.1M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

Revenue Growth
122.22%
122.22%
Profit Growth
$-0.47
64.43%
EPS Growth
$-0.47
81.60%
Operating Margin
-47726.92%
54.89%
ROE
-3530.07%
64.43%
Dividend Yield
0.00%
47.64%

Analyst Recommendations

Strong Buy
Buy
Hold
Sell
Strong Sell

Price Targets

Low$0.41
Average$0.41
High$0.41

Company Profile

BioSig Technologies, Inc., together with its subsidiaries, operates as medical device company. The company's proprietary product includes precise uninterrupted real-time evaluation of electrograms electrophysiology (PURE EP) system, a signal processing platform that combines hardware and software to address known challenges associated to signal acquisition that enables electrophysiologists to see signals and analyze in real-time. It also focuses on enhancing intracardiac signal acquisition and diagnostic information for the procedures of atrial fibrillation, as well as is designed to address long-standing limitations that slow and disrupt cardiac catheter ablation procedures. The company has a research agreement with University of Minnesota to develop novel therapies to treat sympathetic nervous system diseases; and a strategic collaboration with the Mayo Foundation for Medical Education and Research to develop an AI-and machine learning software solution for PURE EP systems. BioSig Technologies, Inc. was incorporated in 2009 and is headquartered in Westport, Connecticut.

CEO

Anthony Amato

Employees

5

Headquarters

55 Greens Farms Road, Los Angeles, CT

Founded

2014

Frequently Asked Questions

;